This drug class confers benefits in diabetic patients with heart failure, CV disease, and renal disease, but it is also associated with major adverse events.
Malignant hyperthermia must be treated rapidly to avoid fatality, and despite its rarity, healthcare facilities that use known triggering agents must be fully prepared to treat it.